Where next with HDL assays?

Area of Science:

• Cardiovascular Research
• Lipid Metabolism
• Biomarker Discovery

Background:

• The inverse relationship between HDL cholesterol (HDL-C) and cardiovascular disease (CVD) is well-established.
• However, interventions targeting HDL-C have not consistently reduced CVD risk, suggesting limitations in using HDL-C alone.
• HDL (high-density lipoprotein) is a complex particle, and its function, composition, and particle concentration may be more indicative of CVD risk than HDL-C levels.

Purpose of the Study:

• To review recent findings on HDL composition, particle concentrations, and cholesterol efflux capacity in relation to CVD.
• To highlight the need for improved understanding of HDL's role in CVD beyond HDL-C.
• To identify potential novel biomarkers and therapeutic targets for CVD prevention and treatment.

Main Methods:

• Review of recent scientific literature on HDL and CVD.
• Analysis of studies examining HDL composition, particle concentrations, and functional assays (e.g., cholesterol efflux capacity).
• Identification of trends and discrepancies in HDL research related to CVD.

Main Results:

• Recent research emphasizes HDL composition, particle concentrations, and cholesterol efflux capacity as key determinants of CVD risk.
• Functional aspects and subpopulations of HDL particles are increasingly recognized as crucial in understanding HDL's role in CVD.
• Discrepancies exist among studies due to a lack of standardization in HDL assays.

Conclusions:

• HDL-C alone is insufficient for accurately assessing CVD risk.
• HDL particle characteristics and functionality offer more reliable insights into CVD.
• Standardized assays are urgently needed to advance HDL research and its clinical application in CVD.